Invossa (tonogenchoncel-L) / Kolon Life Sci 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Enrollment closed, Trial completion date, Trial primary completion date:  Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee (clinicaltrials.gov) -  Jan 24, 2024   
    P3,  N=511, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Jul 2026 Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Feb 2026 | Trial primary completion date: Aug 2024 --> Feb 2024
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Trial completion date, Trial initiation date, Trial primary completion date:  A Study to Determine the Safety and Efficacy of TG-C in Subjects With Symptomatic Early Hip Osteoarthritis (clinicaltrials.gov) -  Dec 23, 2022   
    P2,  N=255, Not yet recruiting, 
    Our results demonstrated that TG-C exerted potent analgesic effects in a rat MIA model of OA pain by inhibiting the upregulation of pain mediators and modulating neuronal sensitization. Trial completion date: Oct 2023 --> Oct 2024 | Initiation date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2023 --> Oct 2024
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Enrollment open, Trial completion date, Trial primary completion date:  Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee (clinicaltrials.gov) -  Jan 4, 2022   
    P3,  N=510, Recruiting, 
    Trial completion date: Oct 2023 --> Oct 2024 | Initiation date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2023 --> Oct 2024 Not yet recruiting --> Recruiting | Trial completion date: Sep 2021 --> Jun 2025 | Trial primary completion date: Sep 2021 --> Jun 2024
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Enrollment open, Trial completion date, Trial primary completion date:  A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee (clinicaltrials.gov) -  Dec 16, 2021   
    P3,  N=510, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Sep 2021 --> Jun 2025 | Trial primary completion date: Sep 2021 --> Jun 2024 Active, not recruiting --> Recruiting | Trial completion date: Oct 2024 --> Jun 2025 | Trial primary completion date: Oct 2023 --> Jun 2024
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee (clinicaltrials.gov) -  May 13, 2020   
    P3,  N=510, Active, not recruiting, 
    Active, not recruiting --> Recruiting | Trial completion date: Oct 2024 --> Jun 2025 | Trial primary completion date: Oct 2023 --> Jun 2024 Suspended --> Active, not recruiting | Trial completion date: Apr 2022 --> Oct 2024 | Trial primary completion date: Apr 2021 --> Oct 2023
  • ||||||||||  Invossa K (tonogenchoncel-L) / Kolon Life Science, Glybera (alipogene tiparvovec) / uniQure, Chiesi, Xenon
    Journal:  The Landscape of Cellular and Gene Therapy Products: Cost, Approvals, and Discontinuations. (Pubmed Central) -  Mar 20, 2020   
    Majority of the gene therapies received orphan designation by the regulatory authorities and had conditional approvals while less than a quarter of cellular therapies received the orphan designation. Most of the gene therapies are approved for rare diseases with smaller patient population, companies find it difficult to make profits which results in market withdrawal of the therapies.
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Enrollment closed:  A Post Marketing Surveillance Study of INVOSSA K Inj. (clinicaltrials.gov) -  May 28, 2019   
    P=N/A,  N=3000, Active, not recruiting, 
    Most of the gene therapies are approved for rare diseases with smaller patient population, companies find it difficult to make profits which results in market withdrawal of the therapies. Recruiting --> Active, not recruiting
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Trial completion date, Trial initiation date, Trial primary completion date:  A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee (clinicaltrials.gov) -  Apr 19, 2018   
    P3,  N=510, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Sep 2021 --> Apr 2022 | Trial primary completion date: Sep 2021 --> Apr 2021 Trial completion date: Jun 2021 --> Sep 2021 | Initiation date: Apr 2018 --> Jul 2018 | Trial primary completion date: Jun 2021 --> Sep 2021
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Trial completion date, Trial initiation date, Trial primary completion date:  Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee (clinicaltrials.gov) -  Apr 19, 2018   
    P3,  N=510, Not yet recruiting, 
    Trial completion date: Jun 2021 --> Sep 2021 | Initiation date: Apr 2018 --> Jul 2018 | Trial primary completion date: Jun 2021 --> Sep 2021 Trial completion date: Jun 2021 --> Sep 2021 | Initiation date: Apr 2018 --> Jul 2018 | Trial primary completion date: Jun 2021 --> Sep 2021
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Enrollment closed, Trial initiation date:  The Efficacy and Safety of Invossa K Injection in Patients Diagnosed With Knee Osteoarthritis (clinicaltrials.gov) -  Mar 7, 2018   
    P3,  N=146, Active, not recruiting, 
    Trial completion date: Jun 2021 --> Sep 2021 | Initiation date: Apr 2018 --> Jul 2018 | Trial primary completion date: Jun 2021 --> Sep 2021 Not yet recruiting --> Active, not recruiting | Initiation date: Jan 2018 --> Feb 2018
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Trial completion:  Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis (clinicaltrials.gov) -  Sep 2, 2015   
    P3,  N=163, Completed, 
    Not yet recruiting --> Active, not recruiting | Initiation date: Jan 2018 --> Feb 2018 Active, not recruiting --> Completed
  • ||||||||||  Invossa (tonogenchoncel-L) / Kolon Life Sci
    Enrollment closed:  Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis (clinicaltrials.gov) -  Aug 21, 2014   
    P3,  N=156, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting